These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9767867)

  • 1. [Anterior uveitis in HIV-infected patients. 3 cases in patients treated with an antiprotease].
    Fournier S; Deplus S; Janier M; Poinsignon Y; Decazes JM; Modai J
    Presse Med; 1998 May; 27(18):844-8. PubMed ID: 9767867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute hepatitis in a patient treated with saquinavir and ritonavir: absence of cross-toxicity with indinavir.
    Vandercam B; Moreau M; Horsmans C; Gala JL
    Infection; 1998; 26(5):313. PubMed ID: 9795794
    [No Abstract]   [Full Text] [Related]  

  • 3. Sarcoidosis-related anterior uveitis in a patient with human immunodeficiency virus.
    Lee AK; Chronister CL
    J Am Optom Assoc; 1999 Jun; 70(6):384-90. PubMed ID: 10437340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uveitis following administration of the protease inhibitor indinavir to a patient with AIDS.
    Gariano RF; Cooney EL
    Clin Infect Dis; 1997 Mar; 24(3):529. PubMed ID: 9114223
    [No Abstract]   [Full Text] [Related]  

  • 5. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
    Manfredi R; Chiodo F
    J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifabutin-associated anterior uveitis in patients infected with human immunodeficiency virus.
    Schimkat M; Althaus C; Becker K; Sundmacher R
    Ger J Ophthalmol; 1996 Jul; 5(4):195-201. PubMed ID: 8854102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperlipidemia associated with the use of protease inhibitors.
    Smith JH; Martin GJ; Decker CF
    Clin Infect Dis; 2000 Jul; 31(1):207-8. PubMed ID: 10913432
    [No Abstract]   [Full Text] [Related]  

  • 8. [Treatment of HIV infections and AIDS with protease inhibitor and two nucleoside analogs].
    Jensen-Fangel S; Larsen L; Thomsen HF; Nielsen LP; Black FT; Obel N
    Ugeskr Laeger; 1999 Mar; 161(12):1751-4. PubMed ID: 10210974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diabetes and hyperglycemia in patients under treatment for HIV infection with the protease inhibitors indavir, ritonavir, saquinavir as well as nelfinavir (in development, but not yet released].
    Pharm Unserer Zeit; 1997 Dec; 26(6):317. PubMed ID: 9513575
    [No Abstract]   [Full Text] [Related]  

  • 10. [Acute coronary syndromes in patients treated with HIV protease inhibitors].
    Barthélémy O; Escaut L; Vayre F; Gallet B; Pulik M; Heloire F; Vittecoq D
    Presse Med; 2002 Mar; 31(8):343-8. PubMed ID: 11913076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A patient's guide to protease inhibitors.
    Elperin A; Sax P
    AIDS Clin Care; 1996 Oct; 8(10):83-4. PubMed ID: 11363988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type 2 diabetes in association with HIV-1 protease inhibitors in HIV-infected patients.
    Chronister CL; Gurwood AS
    J Am Optom Assoc; 1998 Nov; 69(11):695-8. PubMed ID: 9844321
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.
    Justesen US; Fox Z; Pedersen C; Cahn P; Gerstoft J; Clumeck N; Losso M; Peters B; Obel N; Castagna A; Dragsted UB; Lundgren JD;
    Basic Clin Pharmacol Toxicol; 2007 Nov; 101(5):339-44. PubMed ID: 17910618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The choice of HIV protease inhibitor: indinavir is currently the best option.
    Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ritonavir and indinavir one year later.
    TreatmentUpdate; 2001; 12(12):6-7. PubMed ID: 11570094
    [No Abstract]   [Full Text] [Related]  

  • 16. Risk factors for ritonavir intolerance and outcome after change to indinavir.
    Casado JL; Perez-Elías MJ; Antela A; Martí-Belda P; de Lucas S; Muñoz V; Guerrero A
    AIDS; 1998 Feb; 12(3):335-6. PubMed ID: 9580044
    [No Abstract]   [Full Text] [Related]  

  • 17. Using ritonavir with indinavir in cases of virologic failure.
    TreatmentUpdate; 2001; 12(12):7. PubMed ID: 11570095
    [No Abstract]   [Full Text] [Related]  

  • 18. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
    Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
    J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-induced uveitis in aids patients: two case reports.
    Bazewicz M; Fikri J; Martin CH; Libois A; Meunier A; Frippiat F; Caspers L; Willermain F
    Bull Soc Belge Ophtalmol; 2011; (318):19-23. PubMed ID: 22003760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.